Protein-Bound Uremic Retention Solutes

Advances in Renal Replacement Therapy

Volumn 10, Issue 4, 2003, Pages 310-320

  Brunet, Philippe ^a,b   Dou, Laetitia ^a   Cerini, Claire ^a   Berland, Yvon ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

Author keywords

3 carboxy 4 methyl 5 propyl 2 furan propionic acid; Chronic renal failure; Hippuric acid; Homocysteine; Indoxyl sulfate; P cresol; Protein bound solutes; Uremic retention solutes

Indexed keywords

3 CARBOXY 4 METHYL 5 PROPYL 2 FURAN PROPIONIC ACID; AMMONIA; AST 120; CYANOCOBALAMIN; FOLIC ACID; HIPPURIC ACID; HOMOCYSTEINE; INDICAN; PARA CRESOL; PROPIONIC ACID DERIVATIVE; PYRIDOXINE; SORBENT; UNCLASSIFIED DRUG;

ANEMIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE COURSE; DRUG EXCRETION; DRUG METABOLISM; ENDOTHELIUM CELL; EPILEPSY; GLUCOSE UTILIZATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; LEUKOCYTE ADHERENCE; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; METABOLIC ACIDOSIS; MITOCHONDRIAL RESPIRATION; NEUROLOGIC DISEASE; PATHOGENESIS; PERITONEAL DIALYSIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; REVIEW; SOLUTE; UREMIA;

EID: 0348048492     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2003.08.002     Document Type: Article

References (100)

1. Vanholder R, De Smet R, Lameire N: Protein-bound uremic solutes: the forgotten toxins. Kidney Int 59: S266-270, 2001 (suppl)
2. Vanholder R, De Smet R, Lameire NH: Redesigning the map of uremic toxins. Contrib Nephrol 133:42-70, 2001
3. Vanholder R, Hoefliger N, De Smet R, et al: Extraction of protein bound ligands from azotemic sera: Comparison of 12 deproteinization methods. Kidney Int 41:1707-1712, 1992
4. De Smet R, David F, Sandra P, et al: A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 278:1-21, 1998
5. De Smet R, Van Kaer J, Liebich H, et al: Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. Clin Chem 47:901-909, 2001
6. Lesaffer G, De Smet R, Lameire N, et al: Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15:50-57, 2000
7. Curtis HC, Mettler M: Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 126:569-580, 1976
8. Brega A, Prandini P, Amaglio C, et al: Determination of phenol, m-, o- and p-cresol, p-aminophenol and p-nitrophenol in urine by high-performance liquid chromatography. J Chromatogr 535:311-316, 1990
9. Niwa T, Maeda K, Ohki T, et al: A gas chromatographic-mass spectrometric analysis for phenols in uremic serum. Clin Chim Acta 110:51-57, 1981
10. Niwa T: Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 39:108-111, 1993
11. Hida M, Aiba Y, Sawamura S, et al: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349-355, 1996
12. Thompson DC, Perera K, Fisher R, et al: Cresol isomers: Comparison of toxic potency in rat liver slices. Toxicol Appl Pharmacol 125:51-58, 1994
13. Madyastha KM, Paul Raj C: Evidence for the formation of a known toxin, p-cresol, from menthofuran. Biochem Biophys Res Commun 177:440-446, 1991
14. Vanholder R, De Smet R, Lesaffer G: P-cresol: A toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 14:2813-2815, 1999
15. Yehuda S, Carasso RL, Mostofsky DI: Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol 254:193-198, 1994
16. D'Hooge R, Van de Vijver G, Van Bogaert PP, et al: Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 63:1764-1775, 2003
17. Kitagawa A: Effects of cresols (o-, m-, and p-isomers) on the bioenergetic system in isolated rat liver mitochondria. Drug Chem Toxicol 24:39-47, 2001
18. Elliott AA, Elliott JR: Voltage-dependent inhibition of RCK1 K+ channels by phenol, p-cresol, and benzyl alcohol. Mol Pharmacol 51:475-483, 1997
19. Keweloh H, Diefenbach R, Rehm HJ: Increase of phenol tolerance of Escherichia coli by alterations of the fatty acid composition of the membrane lipids. Arch Microbiol 157:49-53, 1991
20. Thompson DC, Perera K, London R: Quinone methide formation from para isomers of methylphenol (cresol), ethylphenol, and isopropylphenol: relationship to toxicity. Chem Res Toxicol 8:55-60, 1995
21. Thompson DC, Perera K, London R: Studies on the mechanism of hepatotoxicity of 4-methylphenol (p-cresol): Effects of deuterium labeling and ring substitution. Chem Biol Interact 101:1-11, 1996
22. Vanholder R, De Smet R, Waterloos MA, et al: Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 47:510-517, 1995
23. Dou L, Cerini C, Brunet P, et al: P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 62:1999-2009, 2002
24. Wratten ML, Tetta C, De Smet R, et al: Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 17:134-141, 1999
25. Abreo K, Sella M, Gautreaux S, et al: P-Cresol, a uremic compound, enhances the uptake of aluminum in hepatocytes. J Am Soc Nephrol 8:935-942, 1997
26. Yokoyama MT, Tabori C, Miller ER, et al: The effects of antibiotics in the weanling pig diet on growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 35:1417-1424, 1982
27. De Smet R, Van Kaer J, Van Vlem B, et al: Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 49:470-478, 2003
28. Lesaffer G, De Smet R, D'heuvaert T, et al: Kinetics of the protein-bound, lipophilic, uremic toxin p-cresol in healthy rats. Life Sci 69:2237-2248, 2001
29. Lameire N, Vanholder R, De Smet R: Uremic toxins and peritoneal dialysis. Kidney Int 59:S292-S297, 2001 (suppl)
30. Niwa T, Ise M, Miyazaki T, et al: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 65:82-87, 1993
31. Depner TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 20:511-518, 1981
32. Sarnatskaya VV, Lindup WE, Niwa T, et al: Effect of protein-bound uraemic toxins on the thermodynamic characteristics of human albumin. Biochem Pharmacol 63:1287-1296, 2002
33. Gorst-Allman CP, Puchta V, Spiteller G: Investigations of the origin of the furan fatty acids (F-acids). Lipids 23:1032-1036, 1988
34. Hannemann K, Puchta V, Simon E, et al: The common occurrence of furan fatty acids in plants. Lipids 24:296-298, 1989
35. McTigue JJ, Henderson SJ, Lindup WE: Excretion of the uraemic metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human urine. Nephron 55:214-215, 1990
36. Sato M, Koyama M, Miyazaki T, et al: Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients. Nephron 74:419-421, 1996
37. Liebich HM, Bubeck JI, Pickert A, et al: Hippuric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in serum and urine. Analytical approaches and clinical relevance in kidney diseases. J Chromatogr 500:615-627, 1990
38. Niwa T, Yazawa T, Kodama T, et al: Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 56:241-245, 1990
39. Henderson SJ, Lindup WE: Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 263:54-60, 1992
40. Costigan MG, Lindup WE: Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 49:634-638, 1996
41. Tsutsumi Y, Deguchi T, Takano M, et al: Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat. Pharmacol Exp Ther 303:880-887, 2002
42. Sakai T, Takadate A, Otagiri M: Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 18:1755-1761, 1995
43. Niwa T, Takeda N, Maeda K, et al: Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clin Chim Acta 173:127-138, 1988
44. Mabuchi H, Nakahashi H: Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia. Clin Chim Acta 167:89-96, 1987
45. Costigan MG, Yaqoob M, Lindup WE: Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant. Nephrol Dial Transplant 11:803-807, 1996
46. Niwa T, Asada H, Tsutsui S, et al: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol 15:463-467, 1995
47. Lim CF, Bernard BF, de Jong M, et al: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 76:318-324, 1993
48. Mabuchi H, Nakahashi H: Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 49:281-283, 1988
49. Niwa T, Aiuchi T, Nakaya K, et al: Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 39:92-96, 1993
50. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124:96-104, 1994
51. Niwa T, Ise M, Miyazaki T: Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 14:207-212, 1994
52. Miyazaki T, Ise M, Seo H, et al: Idoxyl sulfate stimulates renal synthesis of TGF-β1, TIMP-1 and pro-α1(I) collagen in uremic rat kidneys. Kidney Int 52:S15-S22, 1997 (suppl)
53. Miyazaki T, Ise M, Hirata M, et al: Indoxyl sulfate stimulates renal synthesis of transforming growth factor-β1 and progression of renal failure. Kidney Int 52:S211-S214, 1997 (suppl)
54. Niwa T: Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16:167-182, 1996
55. Niwa T, Nomura T, Sugiyama S, et al: The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 52:S23-S28, 1997 (suppl)
56. Miyazaki T, Aoyama I, Ise M, et al: An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 15:1773-1781, 2000
57. Enomoto A, Takeda M, Tojo A, et al: Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 13:1711-1720, 2002
58. Motojima M, Hosokawa A, Yamato H, et al: Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol 135:555-563, 2002
59. Vanholder R, Van Landschoot N, De Smet R, et al: Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 33:996-1004, 1988
60. Dasgupta A, Paul A, Wells A: Uremic sera contain inhibitors that block digitoxin-valproic acid interaction. Am J Med Sci 322:204-208, 2001
61. Ohtsuki S, Asaba H, Takanaga H, et al: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: Its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66, 2002
62. Motojima M, Nishijima F, Ikoma M, et al: Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 40:461-469, 1991
63. Farrell PC, Gotch FA, Peters JH, et al: Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis. Nephron 20:40-46, 1978
64. St Peter WL, Lewis MJ, Macres MG: Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients. Am J Kidney Dis 32:470-474, 1998
65. Pickert A, Bauerle A, Liebich HM: Determination of hippuric acid and furanic acid in serum of dialysis patients and control persons by high-performance liquid chromatography. J Chromatogr 495:95-104, 1989
66. Zimmerman L, Jornvall H, Bergstrom J: Phenylacetylglutamine and hippuric acid in uremic and healthy subjects. Nephron 55:265-271, 1990
67. De Smet R, Vogeleere P, Van Kaer J, et al: Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. J Chromatogr 847:141-153, 1999
68. Boumendil-Podevin EF, Podevin RA, Richet G: Uricosuric agents in uremic sera. Identification of indoxyl sulfate and hippuric acid. J Clin Invest 55:1142-1152, 1975
69. Porter RD, Cathcart-Rake WF, Wan SH, et al: Secretory activity and aryl acid content of serum, urine, and cerebrospinal fluid in normal and uremic man. J Lab Clin Med 85:723-731, 1975
70. Dzurik R, Spustova V, Gerykova M: Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency. Adv Exp Med Biol 223:105-109, 1987
71. Schoots AC, De Vries PM, Thiemann R, et al: Biochemical and neurophysiological parameters in hemodialyzed patients with chronic renal failure. Clin Chim Acta 185:91-107, 1989
72. Dzurik R, Spustova V, Krivosikova Z, et al: Hippurate participates in the correction of metabolic acidosis. Kidney Int 78:S278-281, 2001 (suppl)
73. Liebich HM, Pickert A, Tetschner B: Gas chromatographic and gas chromatographic-mass spectrometric analysis of organic acids in plasma of patients with chronic renal failure. J Chromatogr 289:259-266, 1984
74. Liebich HM, Risler T, Fischer U, et al: Gas chromatographic determination of hippuric acid and a furancarboxylic acid in plasma of patients with kidney diseases. J Chromatogr 399:291-294, 1987
75. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98:5-7, 1996
76. Bostom AG, Shemin D, Laplane KL, et al: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114:93-103, 1995
77. Nakanishi T, Otaki Y, Hasuike Y, et al: Association of hyperhomocysteinemia with plasma sulfate and urine sulfate excretion in patients with progressive renal disease. Am J Kidney Dis 40:909-915, 2002
78. McGregor DO, Dellow WJ, Lever M, et al: Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int 59:2267-2272, 2001
79. Key NS, McGlennen RC: Hyperhomocyst(e)inemia and thrombophilia. Arch Pathol Lab Med 126:1367-1375, 2002
80. Fodinger M, Mannhalter C, Wolfl G, et al: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:517-523, 1997
81. Moustapha A, Naso A, Nahlawi M, et al: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97:138-141, 1998
82. Mallamaci F, Zoccali C, Tripepi G, et al: The CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61:609-614, 2002
83. Suliman ME, Qureshi AR, Barany P, et al: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 57:1727-1735, 2000
84. Tsai JC, Perrella MA, Yoshizumi M, et al: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 91:6369-6373, 1994
85. Blacher J, Demuth K, Guerin AP, et al: Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 12:248-255, 1999
86. Massy ZA: Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant 15:81-91, 2000 (suppl)
87. Van Guldener C, Janssen MJ, Lambert J, et al: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 13:106-112, 1998
88. Thambyrajah J, Landray MJ, McGlynn FJ, et al: Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 102:871-875, 2000
89. Massy ZA, Ceballos I, Chadefaux-Vekemens B, et al: Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int 59:S243-S245, 2001 (suppl)
90. Dierkes J, Domrose U, Ambrosch A, et al: Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 51:108-115, 1999
91. Van Tellingen A, Grooteman MP, Bartels PC, et al: Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 59:342-347, 2001
92. Friedman AN, Bostom AG, Levey AS, et al: Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J Am Soc Nephrol 13:265-268, 2002
93. Moustapha A, Gupta A, Robinson K, et al: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 55:1470-1475, 1999
94. Ducloux D, Heuze-Lecornu L, Gibey R, et al: Dialysis adequacy and homocyst(e)ine concentrations in peritoneal dialysis patients. Nephrol Dial Transplant 14:728-731, 1999
95. Vychytil A, Fodinger M, Papagiannopoulos M, et al: Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 55:2054-2061, 1999
96. Brulez HF, van Guldener C, Donker AJ, et al: The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 14:154-159, 1999
97. Misra M, Vonesh E, Van Stone JC, et al: Effect of cause and time of dropout on the residual GFR: A comparative analysis of the decline of GFR on dialysis. Kidney Int 59:754-763, 2001
98. Vanholder R, Argiles A, Baurmeister U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
99. Abe T, Abe T, Ageta S, et al: A new method for removal of albumin-binding uremic toxins: Efficacy of an albumin-dialysate. Ther Apher 5:58-63, 2001
100. Fagugli RM, De Smet R, Buoncristiani U, et al: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40:339-347, 2002